Purchase this article with an account.
G. Dethorey, N. Leveziel, A. Glacet-Bernard, F. Lalloum, A. Hay, R. Tahiri, E. Champion, E. H. Souied; Efficacy of Ranibizumab versus PDT in Myopic Choroidal Neovascularisation. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2204.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To compare the efficacy of intra-vitreal injections of ranibizumab to photodynamic therapy (PDT) for choroidal neovascularization attribuable to high myopia.
A retrospective analysis of myopic patients treated with ranibizumab (IVT) (group 1), or with PDT (group 2). All patients underwent a complete ophthalmic examination included fundus examination, fluorescein angiography and OCT. Patients included in this study had high myopia (axial length ≥ 26mm or ametropia ≤ -6D) associated with choroidal neovascularisation. All patients were naïve for any treatment. The primary outcomes were the change in best corrected Snellen visual acuity (BCVA) and central retinal thickness (CRT) on OCT between first and final examination.
19 eyes of 19 patients (15 women, 4 men; mean age= 55 years ± 9) treated with ranibizumab injections, and 34 eyes of 34 patients (25 women, 9 men; mean age= 53 years ±14) treated with PDT were included in this study. The mean follow-up was 11 months (±5 months) and the mean number of injections was 2,5 (±0.8) in the group 1. The mean BVCA improved from 20/100 to 20/50 and CRT decreased from 353,3 to 259,2 µm at final examination in the group 1. The mean follow-up was 28 months (±15 months) and number of PDT was 2,0 (±0.9) in the group 2. The mean BVCA decreased from 20/80 to 20/100 and CRT raised from 189,6 to 209,1µ at final examination in the group 2.
Intravitreal injections of ranibizumab seem to be an effective treatment, superior to PDT, for choroidal neovascularisation associated to high myopia. However, other studies are needed to confirm these preliminary results.
This PDF is available to Subscribers Only